HUP0001293A1 - Heterocyclic compounds and their use for inhibiting betha-amyloid peptide - Google Patents
Heterocyclic compounds and their use for inhibiting betha-amyloid peptideInfo
- Publication number
- HUP0001293A1 HUP0001293A1 HU0001293A HUP0001293A HUP0001293A1 HU P0001293 A1 HUP0001293 A1 HU P0001293A1 HU 0001293 A HU0001293 A HU 0001293A HU P0001293 A HUP0001293 A HU P0001293A HU P0001293 A1 HUP0001293 A1 HU P0001293A1
- Authority
- HU
- Hungary
- Prior art keywords
- betha
- inhibiting
- heterocyclic compounds
- amyloid peptide
- general formula
- Prior art date
Links
- 150000002391 heterocyclic compounds Chemical class 0.000 title 1
- 230000002401 inhibitory effect Effects 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000000843 powder Substances 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D257/04—Five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/08—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D277/10—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/08—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D277/12—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
Abstract
Atalálmány tárgyát az (I) általánős képletű vegyületek, valamint azezeket tartalmazó gyógyászati készítmények képezik, amelyekeredményesen alkalmazhatók az Alzheimer-kór kezelésére. Az (I)általánős képletben A, B és C jelentése számős különböző csőpőrt,amelyek jelentése az 1. igénypőntban megadőtt. ŕThe subject of the invention is the compounds of general formula (I) as well as the medicinal preparations containing them, which can be effectively used for the treatment of Alzheimer's disease. In the general formula (I), A, B and C mean several different pipe powders, the meanings of which are given in point 1. ŕ
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US80826397A | 1997-02-28 | 1997-02-28 |
Publications (2)
Publication Number | Publication Date |
---|---|
HUP0001293A1 true HUP0001293A1 (en) | 2000-08-28 |
HUP0001293A3 HUP0001293A3 (en) | 2000-09-28 |
Family
ID=25198310
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU0001293A HUP0001293A3 (en) | 1997-02-28 | 1998-02-27 | Heterocyclic compounds and their use for inhibiting betha-amyloid peptide |
Country Status (22)
Country | Link |
---|---|
EP (1) | EP0968198A1 (en) |
JP (1) | JP2001513107A (en) |
KR (1) | KR20000075767A (en) |
CN (1) | CN1253554A (en) |
AR (1) | AR011164A1 (en) |
AU (1) | AU6662298A (en) |
BR (1) | BR9807876A (en) |
CA (1) | CA2278674A1 (en) |
CO (1) | CO4920244A1 (en) |
EA (1) | EA199900778A1 (en) |
HR (1) | HRP980093A2 (en) |
HU (1) | HUP0001293A3 (en) |
ID (1) | ID22873A (en) |
IL (1) | IL130851A0 (en) |
NO (1) | NO994016L (en) |
NZ (1) | NZ336613A (en) |
PE (1) | PE59399A1 (en) |
PL (1) | PL335424A1 (en) |
TR (1) | TR199902071T2 (en) |
WO (1) | WO1998038177A1 (en) |
YU (1) | YU7998A (en) |
ZA (1) | ZA981627B (en) |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6635632B1 (en) | 1996-12-23 | 2003-10-21 | Athena Neurosciences, Inc. | Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds |
CA2307221A1 (en) * | 1997-12-22 | 1999-07-01 | Elan Pharmaceuticals, Inc. | Polycyclic .alpha.-amino-e-caprolactams and related compounds |
US6509331B1 (en) | 1998-06-22 | 2003-01-21 | Elan Pharmaceuticals, Inc. | Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds |
US6569851B1 (en) | 1998-06-22 | 2003-05-27 | Elan Pharmaceutials, Inc. | Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds |
US6552013B1 (en) | 1998-06-22 | 2003-04-22 | Elan Pharmaceuticals, Inc. | Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds |
US6774125B2 (en) | 1998-06-22 | 2004-08-10 | Elan Pharmaceuticals, Inc. | Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds |
US6528505B1 (en) | 1998-06-22 | 2003-03-04 | Elan Pharmaceuticals, Inc. | Cyclic amino acid compounds pharmaceutical compositions comprising same and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds |
JP2002518481A (en) * | 1998-06-22 | 2002-06-25 | エラン ファーマシューティカルズ,インコーポレイテッド | Compounds for inhibiting the release of β-amyloid peptide and / or its synthesis |
US6737038B1 (en) | 1998-11-12 | 2004-05-18 | Bristol-Myers Squibb Company | Use of small molecule radioligands to discover inhibitors of amyloid-beta peptide production and for diagnostic imaging |
CA2360740A1 (en) | 1999-03-02 | 2000-09-08 | Boehringer Ingelheim Pharmaceuticals, Inc. | Compounds useful as reversible inhibitors of cathepsin s |
US7160880B1 (en) | 1999-05-14 | 2007-01-09 | Cenes Limited | Short-acting benzodiazepines |
GB9911803D0 (en) * | 1999-05-20 | 1999-07-21 | Merck Sharp & Dohme | Therapeutic combination |
EP1210338A2 (en) * | 1999-08-05 | 2002-06-05 | IGT Pharma Inc. | 1,4-diazepine derivatives for the treatment of diseases related to the central nervous system |
US6420364B1 (en) | 1999-09-13 | 2002-07-16 | Boehringer Ingelheim Pharmaceuticals, Inc. | Compound useful as reversible inhibitors of cysteine proteases |
US6878363B2 (en) | 2000-05-17 | 2005-04-12 | Bristol-Myers Squibb Pharma Company | Use of small molecule radioligands to discover inhibitors of amyloid-beta peptide production and for diagnostic imaging |
CA2379445C (en) | 2000-06-01 | 2007-08-21 | Bristol-Myers Squibb Pharma Company | Lactams substituted by cyclic succinates as inhibitors of a.beta. protein production |
DE10029077A1 (en) * | 2000-06-13 | 2001-12-20 | Bayer Ag | New heterocyclic-substituted thiazole derivatives, useful as total or selective herbicides, insecticides, acaricides, nematocides, ectoparasiticides or antifouling agents |
US6432944B1 (en) | 2000-07-06 | 2002-08-13 | Bristol-Myers Squibb Company | Benzodiazepinone β-amyloid inhibitors: arylacetamidoalanyl derivatives |
AR039059A1 (en) | 2001-08-06 | 2005-02-09 | Sanofi Aventis | COMPOUND DERIVED FROM ACILAMINOTIAZOL, ITS USE, PROCEDURES TO PREPARE IT, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT, AND INTERMEDIARY COMPOUNDS |
FR2840899B1 (en) * | 2002-06-12 | 2005-02-25 | Sanofi Synthelabo | ACYLAMINOTHIAZOLE DERIVATIVES, THEIR PREPARATION AND THEIR USE IN THERAPEUTICS |
EP1550725A4 (en) | 2002-06-05 | 2010-08-25 | Kaneka Corp | PROCESS FOR PRODUCING OPTICALLY ACTIVE alpha-METHYLCYSTEINE DERIVATIVE |
NZ588431A (en) | 2004-09-17 | 2012-02-24 | Whitehead Biomedical Inst | Using Benzimidazole or Indole compounds with a 1,2-diazole group to Inhibit Alpha-Synuclein Toxicity |
US7449486B2 (en) | 2004-10-19 | 2008-11-11 | Array Biopharma Inc. | Mitotic kinesin inhibitors and methods of use thereof |
UA95907C2 (en) | 2005-05-02 | 2011-09-26 | Эррей Биофарма Инк. | Mitotic kinesin inhibitors and methods of use thereof |
EP1757290A1 (en) | 2005-08-16 | 2007-02-28 | Zentaris GmbH | Novel triazole derivatives as ghrelin analogue ligands of growth hormone secretagogue receptors |
EP2081918A2 (en) | 2006-10-03 | 2009-07-29 | Array Biopharma, Inc. | Mitotic kinesin inhibitors and methods of use thereof |
US8598346B2 (en) * | 2008-07-16 | 2013-12-03 | Bitop Ag | Synthesis of cyclic amidines |
US9133123B2 (en) | 2010-04-23 | 2015-09-15 | Cytokinetics, Inc. | Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use |
AR081626A1 (en) | 2010-04-23 | 2012-10-10 | Cytokinetics Inc | AMINO-PYRIDAZINIC COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND USE OF THE SAME TO TREAT CARDIAC AND SKELETIC MUSCULAR DISORDERS |
AR081331A1 (en) | 2010-04-23 | 2012-08-08 | Cytokinetics Inc | AMINO- PYRIMIDINES COMPOSITIONS OF THE SAME AND METHODS FOR THE USE OF THE SAME |
EP2431035A1 (en) | 2010-09-16 | 2012-03-21 | Æterna Zentaris GmbH | Novel Triazole Derivatives with Improved Receptor Activity and Bioavailability Properties as Ghrelin Antagonists of Growth Hormone Secretagogue Receptors |
US8759380B2 (en) | 2011-04-22 | 2014-06-24 | Cytokinetics, Inc. | Certain heterocycles, compositions thereof, and methods for their use |
US8809372B2 (en) | 2011-09-30 | 2014-08-19 | Asana Biosciences, Llc | Pyridine derivatives |
CN103435549A (en) * | 2013-08-14 | 2013-12-11 | 无锡惠飞生物医药技术有限公司 | 5-methyl-7-amino-5H,7H-dibenzo[b,d]azepin-6-ketone preparation method |
CN105646208B (en) * | 2016-02-24 | 2018-10-16 | 潍坊晶润化工股份有限公司 | The preparation method of methyl pyruvate |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH11506923A (en) * | 1995-06-06 | 1999-06-22 | アセナ ニューロサイエンシーズ,インコーポレイテッド | New cathepsins and methods and compositions for their inhibition |
-
1998
- 1998-02-24 HR HR08/808,236A patent/HRP980093A2/en not_active Application Discontinuation
- 1998-02-24 AR ARP980100812A patent/AR011164A1/en unknown
- 1998-02-26 ZA ZA9801627A patent/ZA981627B/en unknown
- 1998-02-27 AU AU66622/98A patent/AU6662298A/en not_active Abandoned
- 1998-02-27 EP EP98908637A patent/EP0968198A1/en not_active Withdrawn
- 1998-02-27 PL PL98335424A patent/PL335424A1/en unknown
- 1998-02-27 WO PCT/US1998/003373 patent/WO1998038177A1/en not_active Application Discontinuation
- 1998-02-27 CO CO98010854A patent/CO4920244A1/en unknown
- 1998-02-27 HU HU0001293A patent/HUP0001293A3/en unknown
- 1998-02-27 NZ NZ336613A patent/NZ336613A/en unknown
- 1998-02-27 TR TR1999/02071T patent/TR199902071T2/en unknown
- 1998-02-27 ID IDW990811A patent/ID22873A/en unknown
- 1998-02-27 PE PE1998000144A patent/PE59399A1/en not_active Application Discontinuation
- 1998-02-27 KR KR1019997007839A patent/KR20000075767A/en not_active Application Discontinuation
- 1998-02-27 EA EA199900778A patent/EA199900778A1/en unknown
- 1998-02-27 CN CN98802875A patent/CN1253554A/en active Pending
- 1998-02-27 JP JP53773298A patent/JP2001513107A/en active Pending
- 1998-02-27 YU YU7998A patent/YU7998A/en unknown
- 1998-02-27 BR BR9807876-3A patent/BR9807876A/en not_active IP Right Cessation
- 1998-02-27 CA CA002278674A patent/CA2278674A1/en not_active Abandoned
- 1998-02-27 IL IL13085198A patent/IL130851A0/en unknown
-
1999
- 1999-08-19 NO NO994016A patent/NO994016L/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
TR199902071T2 (en) | 2000-01-21 |
AU6662298A (en) | 1998-09-18 |
BR9807876A (en) | 2000-02-29 |
PL335424A1 (en) | 2000-04-25 |
WO1998038177A1 (en) | 1998-09-03 |
NO994016D0 (en) | 1999-08-19 |
NO994016L (en) | 1999-10-18 |
EA199900778A1 (en) | 2000-04-24 |
CA2278674A1 (en) | 1998-09-03 |
YU7998A (en) | 2002-06-19 |
CO4920244A1 (en) | 2000-05-29 |
IL130851A0 (en) | 2001-01-28 |
HUP0001293A3 (en) | 2000-09-28 |
JP2001513107A (en) | 2001-08-28 |
ID22873A (en) | 1999-12-16 |
EP0968198A1 (en) | 2000-01-05 |
KR20000075767A (en) | 2000-12-26 |
CN1253554A (en) | 2000-05-17 |
ZA981627B (en) | 1999-10-05 |
AR011164A1 (en) | 2000-08-02 |
PE59399A1 (en) | 1999-06-21 |
NZ336613A (en) | 2001-10-26 |
HRP980093A2 (en) | 1998-12-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUP0001293A1 (en) | Heterocyclic compounds and their use for inhibiting betha-amyloid peptide | |
BRPI9605663B8 (en) | Bis(resorcinyl) triazines. | |
NO20004803L (en) | Smilagening and anzurogenin for the treatment of Alzheimer's disease | |
HUP0000492A1 (en) | N-(aryl/heteroarylacetyl) amino acid esters, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds | |
HUP9903906A2 (en) | Use of chelating agent clioquinol for the manufacture of a pharmaceutical composition for the treatment of alzheimer's disease | |
FI962557A0 (en) | Use of PLA2 inhibitors for the treatment of Alzheimer's disease | |
EA200000723A1 (en) | DERIVATIVES 2- (PURIN-9-IL) -TETRAHYDROFURAN-3,4-DIOLA | |
NZ237023A (en) | 17beta-substituted-4-aza-5alpha-androstan-3-ones and pharmaceutical compositions | |
BR0212042A (en) | Compound, pharmaceutical composition, method of treating or preventing disease, and use of a compound | |
TR200200068T2 (en) | Mathematical trifluorobutens | |
MY106315A (en) | Pharmaceutical agents | |
BR9714358A (en) | Derivatives of n- (aryl / heteroaryl) amino acid, pharmaceutical compositions comprising them, and methods for inhibiting the release of beta-amyloid peptide and / or its synthesis by using such compounds | |
NO972391L (en) | 2-Substituted 1,2,5-thiadiazolidin-3-one 1,1-dioxides and their preparations and methods | |
HUP9900819A1 (en) | Bicyclic aromatic compounds and their use in human or veterinary medicine, as well as in cosmetology | |
TR199802044T2 (en) | New carbon acid derivatives, production and uses. | |
NO20000771L (en) | Use of fanquinone for the treatment of Alzheimer's disease | |
TR200100637T2 (en) | New natural product derivatives | |
HUP0105308A2 (en) | Eletriptan hydrobromide monohydrate, process for its preparation and pharmaceutical compositions containing the same | |
TR199802042T2 (en) | New carbonic acid derivatives, their production and uses. | |
HUP0100048A2 (en) | Arylsubstituted piperazine-derivatives, useful in the treatement of benign prostatic hyperlasia use of them for producing pharmaceutical compositions and pharmaceutical compositions containing them | |
TR199900662T2 (en) | The use of 1-hydroxy-2-pyridones for the treatment of seborrheic dermatitis | |
TR200401775T4 (en) | Branched modified novel amino derivatives of 3-Amino-1-Phenyl-1H [1,2,4] triazole, method for their manufacture and pharmaceutical compositions containing them | |
ATE260655T1 (en) | USE OF NITROGEN-CONTAINING AROMATIC HETEROCYCLE DERIVATIVES FOR THE TOPICAL TREATMENT OF EPITHERAL DISEASES | |
DE50114335D1 (en) | LH-RH ANTAGONISTS, THEIR PREPARATION AND THEIR USE AS DRUGS | |
ATE40987T1 (en) | ACETYLENIC PHENOXYPROPANOL DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF HIGH BLOOD PRESSURE. |